NCT06561841View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

April 2, 2025

Study Completion Date

April 2, 2025

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

HSK39297

HSK39297 tablets for 24 weeks

Trial Locations (1)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06561841 - A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH） | Biotech Hunter | Biotech Hunter